The Dow Chemical Company

VISIT THE VIRTUAL BOOTH, Contact Details

DIGITAL CONTENT

Interview #SpeakPharma, Vlog #PharmaReel, Data Compilation #PharmaFlow, 27 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

98 All APIs, 94 USDMF, 9 JDMF

EXCIPIENTS

59 All Excipients, 51 USDMF, 3 CEP/COS, 1 JDMF, 2 KDMF, 6 NDC API, 6 Listed Products

EXCIPIENTS BY INGREDIENTS

Hydroxypropyl methylcellulose acetate succinate, Carboxymethyl cellulose sodium, Hypromellose Acetate Succinate, Hydroxypropyl Methylcellulose, Hydroxypropyl Methyl Cellulose, EthylCellulose

EXCIPIENTS BY APPLICATIONS

Coating Systems & Additives, Controlled & Modified Release, Granulation, Rheology Modifiers, Solubilizers, API Stability Enhancers, Direct Compression, Taste Masking, Vegetarian Capsules

REF. STANDARDS & IMPURITIES

1 Others

1 Others

INSPECTIONS & REGISTRATIONS

20 FDA, 4 EDQM, 2 GDUFA, 1 Third-Party Audit

Filters

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]

“Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

This week, SpeakPharma interviews Marie-Armelle Floc’h, Chief of Quality and Regulatory Affairs at HTL Biotechnology, a global leader in the development and the manufacturing of pharmaceutical-grade biopolymers headquartered in Javené, Brittany (France). Since 1992, HTL has pioneered the production of hyaluronic acid (HA) through proprietary biofermentation, achieving unmatched purity and consistency for applications in ophthalmology, dermatology and rheumatology. Floc’h highlights how HTL Biotechnology’s compelling portfolio of pharmaceutical-grade biopolymers is built on uncompromising quality standards. These standards have enabled the company to supply biopolymers for over 30 years without a single batch recall, firmly establishing its reputation for reliability and excellence. She also discusses the inauguration of HTL Biotechnology’s new sterile hyaluronic acid production unit — a major milestone that reinforces the company’s leadership in biopolymer manufacturing and enables the development of innovative formulations combining hyaluronic acid with thermo-sensitive active ingredients. This new capability opens the door to advanced biomedical applications where safety, stability and efficacy must be preserved without compromising the integrity of delicate molecules and which requires the highest quality standards. What distinguishes HTL Biotechnology’s biopolymer platforms in the market today? HTL Biotechnology has built its reputation on delivering pharmaceutical‑grade biopolymers (hyaluronic acid, polynucleotides and recombinant collagen) with unmatched purity and consistency. Since its founding in 1992, the company has focused on premium quality positioning. With more than 30 years of experience, HTL Biotechnology guarantees pharmaceutical-grade biopolymers of exceptional purity and exemplary consistency to our clients. We have had no batch recalls in 30 years, a record that underlines the rigor and reliability embedded in our processes. This was made possible by our fully-integrated site in France, where R&D laboratories, GMP manufacturing, quality control, and regulatory expertise are brought together under one roof. Such integration allows us to support our clients seamlessly throughout their product development journey, from early innovation through to global commercialization.Also, the inauguration of our new sterile hyaluronic acid production unit expands the possibilities for our HA to be used in advanced formulations with thermo-sensitive active ingredients, while upholding the uncompromising quality that defines HTL Biotechnology.Our operations are guided by internationally recognized standards, including ISO 13485 certification, which ensures the quality and safety required by medical device manufacturers worldwide.In addition, our Halal certification provides our customers with a significant advantage in accessing and expanding into markets where these requirements are essential for commercialization.Beyond certifications, our commitment to supporting global growth is reflected in the Drug Master Files we maintain across five continents, enabling our clients to accelerate product registration and bring innovative therapies to markets across the world more efficiently. By combining craftsmanship with pharmaceutical rigor, supported by state-of-the-art equipment and advanced bio-production methods, we ensure that every batch produced not only meets the strictest standards, but also delivers the reliability and consistency needed across the entire healthcare ecosystem. HIGHLIGHTS// Biopolymers with unmatched purity/record of no batch recalls/integrated facility in France/operations guided by global standards/new sterile HA unit for advanced formulations Navigating the complex and evolving regulatory frameworks across global markets can be challenging for healthcare companies. Can you tell us more about how HTL Biotechnology supports its partners in this area? Regulatory support is part of our core premium services offer. We provide pharmaceutical regulatory support to ensure products meet the necessary compliance standards, so our partners can focus on their growth. Our dedicated regulatory professionals bring global and regional expertise, with a team specifically supporting customers in Asia. We offer personalized assistance adapted to their products and to the compliance standards of the target market. This includes personalized case-management support for regulatory file submissions with the concerned health authorities to minimize risks of refusal or delay, with the aim of achieving approval quickly and smoothly.Our offer for regulatory support continues beyond approval. We continuously monitor updates to regulations and provide post-commercialization support to our partners to help them manage any necessary regulatory updates.HIGHLIGHTS// Regulatory support offered as premium service/global and regional expertise/personalized case management for faster approvals/continuous regulatory support How does HTL Biotechnology integrate sustainability and corporate responsibility into its operations? Sustainability is embedded in HTL Biotechnology’s strategic vision and day-to-day operations. In 2024, the company renewed its commitment to environmental responsibility by reinforcing its corporate social responsibility (CSR) roadmap. Tangible progress was made across multiple fronts: a 27 percent reduction in greenhouse gas emissions per kilogram of HA produced between 2021 and 2024, and a 34 percent reduction in water consumption per kilogram of HA since 2020. In 2024, we renewed the ISO 14001:2015 certification for its environmental management system, reflecting rigorous audit protocols and continual improvement cycles. All employees have been trained in the ISO 14001-certified environmental management system, and 78 percent of critical suppliers have signed HTL Biotechnology’s Responsible Purchasing Charter.These results reflect HTL Biotechnology’s structured and proactive approach to reducing its environmental footprint while maintaining the highest standards of quality and compliance.HIGHLIGHTS// Sustainability embedded in strategic vision/strong CSR roadmap with measurable progress/reduction in greenhouse gas emissions/responsible sourcing

Impressions: 2796

VLOG #PharmaReel

[Sponsored by another company]

Partnering with nature to grow foundational medicines

This PharmaReel showcases Centrient Pharmaceuticals, a global leader in sustainable enzymatic antibiotics, antifungals and next-gen statins, with integrated capabilities across intermediates, APIs & finished dosages, with a vision to be the leading, diversified partner for generics marketers.

Impressions: 1604

DATA COMPILATION #PharmaFlow

[Sponsored by another company]

CDMO Activity Tracker: Lupin’s CDMO commissions oncology block in India; Cambrex, Axplora, Hovione expand operations

The global contract development and manufacturing organization (CDMO) market has been growing at a healthy compound annual growth rate (CAGR) of 9 percent, and is poised to attain a size of US$ 465.24 billion by 2032 from US$ 255.01 billion in 2025.During the current quarter, the sector has witnessed increase in manufacturing capacities and a rapid expansion in specialized modalities. CDMOs are gearing up for higher growth. The global antibody and antibody-drug conjugate (ADC) CDMO market, for instance, was estimated at US$ 21.1 billion in 2024 and is projected to reach US$ 45.8 billion by 2033, growing at a CAGR of 9.38 percent. Similarly, the peptide and oligonucleotide CDMO market was valued at US$ 2.8 billion in 2024, and is expected to grow at 12.8 percent CAGR, attaining a size of US$ 8.14 billion by 2033.Even though cell and gene therapies (CGTs) have been facing considerable challenges in recent years, the CDMO market for CGTs is estimated to witness a very high growth rate of 27.92 percent CAGR — catapulting it from an estimated US$ 6.31 billion in 2024 to US$ 74.03 billion by 2034. According to a report by Precedence Research, the integration of artificial intelligence in CGT manufacturing is playing an important role in optimizing cell selection, predicting treatment results and analyzing large datasets that help identify potential issues.With the world facing a growing burden of chronic diseases, and the pharmaceutical industry facing a shortage of in-house manufacturing and R&D capabilities, CDMOs in the global small-molecule market are also witnessing high growth. Currently valued at around US$ 78.01 billion, the market for small molecule CDMOs is growing at 7.14 percent CAGR and is expected to reach US$ 145.12 billion by 2034.Some of the key players in the CDMO space include Lonza, Axplora, Mission CDMO, LGM Pharma, Veranova, EUROAPI, Evonik, Thermo Fisher, Lupin Manufacturing Solutions, Bora Pharmaceuticals, Samsung Biologics, and Syngene. View CDMO Activity Tracker for Q4 2025 (Free Excel Available)Lupin Manufacturing Solutions, Serán BioScience, Alcami Simtra expand capacitiesCDMOs across the globe are increasing capacities. Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of Lupin Limited, commissioned a dedicated oncology Block at its Vizag (India) facility. The high-containment unit enhances LMS’ end-to-end CDMO capabilities for high potent active pharmaceutical ingredients (HPAPIs), supporting oncology programs from preclinical development through commercial manufacturing. American CDMO Serán BioScience completed two of the three new buildings and commenced the construction of a third facility at its new 100,000-square-foot commercial manufacturing campus in Oregon (US). The campus includes a 50,000-square-foot facility dedicated to specialized packaging and supply chain operations.Similarly, Texas-based Mission CDMO has added new large-scale equipment for the production of oral solutions and semi-solids, thereby increasing its annual capacity to 13 million liters.New Jersey-based CDMO Simtra is expanding manufacturing operations in both the US and Germany. In Halle/Westfalen, Germany, Simtra commissioned a conjugation and purification suite and inaugurated a new building equipped with two high-speed isolator lines for syringes and vials. And American CDMO Alcami Corporation has expanded its laboratory services at its Creekstone Drive facility in Durham, North Carolina. View CDMO Activity Tracker for Q4 2025 (Free Excel Available) Cambrex, Axplora, Hovione expand operations; India’s Syngene upgrades its sitesIn other capacity expansion news, US-based CDMO Cambrex has announced a US$ 120 million investment to expand its manufacturing operations in the US. The investment increases the large-scale manufacturing capacity at its Charles City, Iowa site, by 40 percent, taking total capacity close to one million liters.European CDMO Axplora has stated that total investments initiated across its global network in 2025 will exceed €100 million (US$ 117 million). This includes €60 million (US$ 70.4 million) allocated to the ongoing expansion of its Mourenx (France) site, along with €35 million (US$ 41 million) at its Gropello (Italy) facility and €8.5 million (US$ 9.9 million) at its Vizag (India) site, both announced earlier in the year. In addition, Axplora has expanded its ADC manufacturing capabilities at its Le Mans (France) site.India-based Syngene International has announced site upgrades aimed at accelerating drug discovery and development timelines for its clients. The investments include a dedicated peptide laboratory at its Bengaluru site and the introduction of advanced automation across drug metabolism and pharmacokinetics and direct-to-biology workflows in Hyderabad.Portugal-headquartered Hovione has completed an initial US$ 100 million investment cycle to expand its manufacturing site in East Windsor, New Jersey. The expansion supports Hovione’s strategy to grow its US operations and strengthen its integrated capabilities across drug substance, drug product intermediates, and finished drug products. View CDMO Activity Tracker for Q4 2025 (Free Excel Available) Lonza buys microbial testing firm, launches two products for manufacturing CGTsSwiss CDMO Lonza has launched two products — TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium —to expand its GMP-grade solutions for CGT manufacturing. TheraPEAK products are used in FDA-approved therapies and over 130 clinical trials globally. The expanded portfolio provides scalable, regulatory-ready solutions to support workflows from discovery through clinical development.Lonza has also signed an agreement to acquire Redberry SAS, a France-based microbial testing technology company. The acquisition adds Redberry’s Red One rapid microbial detection platform to Lonza’s portfolio.Separately, Oxford Biomedica has signed and closed an asset purchase agreement to acquire a custom-built viral vector manufacturing facility for CGTs in North Carolina (US) from RTP Operating, LLC, a subsidiary of National Resilience Holdco. OXB paid £3.4 million (US$ 4.5 million) for the assets. View CDMO Activity Tracker for Q4 2025 (Free Excel Available) Bora partners Corealis for oral drugs; Piramal, IntoCell join hands for bioconjugates Bora Pharmaceuticals and Corealis Pharma have entered into a strategic alliance to provide end-to-end services for oral soild dose (OSD) development and manufacturing. The collaboration offers a scalable pathway from early development to commercial production for pharmaceutical and biotech companies.Piramal Pharma Solutions has signed a non-exclusive and non-binding MoU with IntoCell. The collaboration combines IntoCell’s proprietary drug-linker technologies with Piramal’s experience in developing and manufacturing ADCs through its ADCelerate platform.In other deals, UK-based eXmoor Pharma has entered into two collaborations to support the development of CGTs. The first is with University College London’s Translational Research Office, while the second is with Royal Free London NHS Foundation Trust’s Cell and Vector Innovation Centre. View CDMO Activity Tracker for Q4 2025 (Free Excel Available) Our viewThe current spate of investments underscores how the CDMO sector is emerging as a capability-driven ecosystem. While incremental capacity additions continue across small molecules and OSD forms, the sharper strategic focus is clearly on high-growth, high-complexity areas such as ADCs, CGTs, peptides and oligonucleotides.

Impressions: 1058

NEWS #PharmaBuzz

[Sponsored by another company]

WHO warns of falsified cough syrup ingredients seized in Pakistan

16 Apr 2024

// REUTERS

UK: EPO Oppositions Newsletter - Surge In Oppositions Matches Surge In Grants

26 Mar 2020

// David Lewin MONKAQ

Takeda's Shire Takeover Seen Facing EU Scrutiny of Drug Research

09 May 2018

// Aoife White BLOOMBERG

Dow's Merck Does An About-Face, Releases Cancer Trial Results

16 Jan 2018

// INVESTORS

DowDuPont completes FMC acquisition, bolsters excipient biz

06 Nov 2017

// Dan Stanton IN PHARMATECHNOLOGIST

Continuous Mfg : suitable excipients & more knowledge required, says Dow

25 Oct 2017

// Flora Southey IN PHARMATECHNOLOGIST

Contact The Dow Chemical Company and get a quotation

The Dow Chemical Company is a supplier offers 79 products (APIs, Excipients or Intermediates).

Find a price of Simethicone bulk with DMF, JDMF offered by The Dow Chemical Company

Find a price of Cholestyramine bulk with JDMF offered by The Dow Chemical Company

Find a price of Dimethicone bulk with JDMF offered by The Dow Chemical Company

Find a price of Amberlite Irp69 bulk with DMF offered by The Dow Chemical Company

Find a price of Cholestyramine bulk with DMF offered by The Dow Chemical Company

Find a price of Lauromacrogol bulk with JDMF offered by The Dow Chemical Company

Find a price of Macrogol bulk with DMF offered by The Dow Chemical Company

Find a price of Simethicone bulk with DMF offered by The Dow Chemical Company

Find a price of XUS43598-SMA Na bulk with JDMF offered by The Dow Chemical Company

Find a price of XUS43598-SMA Ca bulk with JDMF offered by The Dow Chemical Company

Find a price of XUS43598SF Ca bulk with JDMF offered by The Dow Chemical Company

Find a price of Amberlite Irp69 bulk offered by The Dow Chemical Company

Find a price of Aspirin bulk offered by The Dow Chemical Company

Find a price of Cholestyramine bulk offered by The Dow Chemical Company

Find a price of Cyclopropane bulk offered by The Dow Chemical Company

Find a price of Dead On Polystyrene bulk offered by The Dow Chemical Company

Find a price of Decamethylcyclopentasiloxane bulk offered by The Dow Chemical Company

Find a price of Dextropropoxyphene HCl bulk offered by The Dow Chemical Company

Find a price of DPPC bulk offered by The Dow Chemical Company

Find a price of Edetate Sodium bulk offered by The Dow Chemical Company

Find a price of Erythromycin bulk offered by The Dow Chemical Company

Find a price of Erythromycin Stearate bulk offered by The Dow Chemical Company

Find a price of GUANIDINE HYDROCHLORIDE API bulk offered by The Dow Chemical Company

Find a price of Mesalazine bulk offered by The Dow Chemical Company

Find a price of Oxygen bulk offered by The Dow Chemical Company

Find a price of Sevelamer Hydrochloride bulk offered by The Dow Chemical Company

Find a price of Tetracycline bulk offered by The Dow Chemical Company

Find a price of Theophylline bulk offered by The Dow Chemical Company

Find a price of Vinyl Chloride bulk offered by The Dow Chemical Company

Find a price of Xenon Radioisotopes bulk offered by The Dow Chemical Company

Find a price of Zoalene bulk offered by The Dow Chemical Company

Find a price of UNS-TETRAFLUOROETHANE bulk offered by The Dow Chemical Company

Find a price of RHOZYME 41 CONCENTRATE bulk offered by The Dow Chemical Company

Find a price of BIOCRYL, BPA-1050 bulk offered by The Dow Chemical Company

Find a price of BIOCRYL BPA-5050PMN bulk offered by The Dow Chemical Company

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN PITTSBURG, CAL. bulk offered by The Dow Chemical Company

Find a price of TROLENE FM MEDICATED PREMIX bulk offered by The Dow Chemical Company

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MIDLAND, MICHIGAN. bulk offered by The Dow Chemical Company

Find a price of TERGITOL ANIONIC SURFACTANT 4 bulk offered by The Dow Chemical Company

Find a price of PZ 5561.21 (DURAFILM PRODUCT) bulk offered by The Dow Chemical Company

Find a price of SILICONE X-251 bulk offered by The Dow Chemical Company

Find a price of CHIMERIC (MURINE VARIABLE, HUMAN CONSTANT) MONOCLONAL ANTIBODY (CC49) TO TUMOR ASSOCIATED GLYCOPROTEIN (TAG)-72 bulk offered by The Dow Chemical Company

Find a price of DOW 132 (4-TERT-BUTYL-2-CHLOROPHENYLMETHYL METHY PHOSPHORAMIDATE) bulk offered by The Dow Chemical Company

Find a price of MANUF PROCESSES OF CAP-PLATE MENICON & MAFILCON SOFT CONTACT LENS MAT. bulk offered by The Dow Chemical Company

Find a price of SILASTIC 1808 ELASTOMER bulk offered by The Dow Chemical Company

Find a price of SILASTIC 9711 MEDICAL GRADE ELASTOMER bulk offered by The Dow Chemical Company

Find a price of VINYLITE BRAND COATED PAPER VDI 6645 WHITE 1435 bulk offered by The Dow Chemical Company

Find a price of TEFLURANE bulk offered by The Dow Chemical Company

Find a price of X7-2837/Q7-2837 SILICONE EMULSION AND REINFORCING AGENT bulk offered by The Dow Chemical Company

Find a price of POLYGLYCOL E-3350 NF bulk offered by The Dow Chemical Company

Find a price of SILICONE RUBBER DOW CORNING SILASTIC bulk offered by The Dow Chemical Company

Find a price of INVESTIGATIONAL DRUG "MASTER FILE" FOR FUTURE REFS NOTICES T/B SUBMITT bulk offered by The Dow Chemical Company

Find a price of RHOZYME J-25 CONCENTRATE bulk offered by The Dow Chemical Company

Find a price of BROMINATED SALICYLANILIDE bulk offered by The Dow Chemical Company

Find a price of SYNTHETIC SODIUM ALUMINOSILICATE ABSORBENTS (MOLECULAR SIEVES) bulk offered by The Dow Chemical Company

Find a price of HYAMINE 1622 CRYSTALS (BENSETHONIUM CHLORIDE) bulk offered by The Dow Chemical Company

Find a price of UNION CARBIDE'S SENTRY SIMETHICONE USP & 30% EMUL bulk offered by The Dow Chemical Company

Find a price of MURINE MONOCLONAL ANTIBODY (COL-1) TO CEA bulk offered by The Dow Chemical Company

Find a price of 20% OXYGEN, 80% ARGON AS MANUF AT TORRENCIE, CA bulk offered by The Dow Chemical Company

Find a price of MONOCLONAL ANTIBODY CC49 bulk offered by The Dow Chemical Company

Find a price of PERSONNEL HANDLING NEW DRUG SUBSTANCES bulk offered by The Dow Chemical Company

Find a price of PEI 600 POLYETHYLENIMINE bulk offered by The Dow Chemical Company

Find a price of HYAMINE X (QUATERNARY AMMONIUM CHLORIDE COMPOUND) bulk offered by The Dow Chemical Company

Find a price of FACILITIES IN SHIZOUKA, JAPAN bulk offered by The Dow Chemical Company

Find a price of BIOCRYL, BPA-1000 bulk offered by The Dow Chemical Company

Find a price of BIO-RELEASE SILICONE RELEASE COATING SYSTEM, HEMLOCK, MI bulk offered by The Dow Chemical Company

Find a price of PROPYLENE GLYCOL--TRADE NAME SIRLENE (VET) bulk offered by The Dow Chemical Company

Find a price of ETHYCELLULOSE DISPERSIONS bulk offered by The Dow Chemical Company

Find a price of ASPERKINASE PRODUCTION bulk offered by The Dow Chemical Company

Find a price of ZIRCONIA TEXTILES bulk offered by The Dow Chemical Company

Find a price of FACILITIES & CONTROLS (METHOXY FLURANE) bulk offered by The Dow Chemical Company

Find a price of POLYTHIOL RESIN bulk offered by The Dow Chemical Company

Find a price of UCC MASTER MILKER SYSTEM FOR TC-99 EXTRACTION FROM MO-99 bulk offered by The Dow Chemical Company

Find a price of TERGITOL MONIONIC SURFACTANT 12-M-10 bulk offered by The Dow Chemical Company

Find a price of VERSENE CA. CALCIUM CHELATING AGENT bulk offered by The Dow Chemical Company

Find a price of DISIDIUM DIHYDROGEN VERSENATE, A.R. bulk offered by The Dow Chemical Company

Find a price of POLYMER JR & LR RESINS bulk offered by The Dow Chemical Company

Find a price of HYDROXYETHYL METHACRYLATE 94% bulk offered by The Dow Chemical Company

Find a price of ETHOXYLATED POLYETHYLENIMINE, MONTREK 600E bulk offered by The Dow Chemical Company

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.